Jade Biosciences (JBIO) Other Non-Current Liabilities (2021 - 2025)
Jade Biosciences (JBIO) reported Other Non-Current Liabilities of $70000.0 for Q1 2025, little changed on a YoY basis from $70000.0 in Q1 2024, and down 99.93% quarter-over-quarter from $107.6 million in Q4 2024.
Jade Biosciences (JBIO) Other Non-Current Liabilities (2021 - 2025) Analysis & Trends
Jade Biosciences has reported Other Non-Current Liabilities for 5 years, with the latest figure at $70000.0 in Q1 2025.
- For the quarter ending Q1 2025, Other Non-Current Liabilities changed 0.0% year-over-year to $70000.0; the trailing twelve-month figure through Mar 2025 stood at $70000.0 (changed 0.0% YoY), and the FY2024 full-year result was $107.6 million, up 153614.29% from the prior year.
- Other Non-Current Liabilities for Q1 2025 stood at $70000.0, down from $107.6 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $107.6 million in Q4 2024, with the low at $13000.0 in Q4 2021.
- Historically, Other Non-Current Liabilities has averaged $7.7 million across 5 years, with a median of $70000.0 in 2023.
- Annual changes were most pronounced in 2023 — Other Non-Current Liabilities declined 1.41% — and 2024, when it jumped 153614.29%.
- Jade Biosciences' Other Non-Current Liabilities stood at $13000.0 in 2021, then soared by 446.15% to $71000.0 in 2022, then retreated by 1.41% to $70000.0 in 2023, then jumped by 153614.29% to $107.6 million in 2024, then sank by 99.93% to $70000.0 in 2025.
- The last three Other Non-Current Liabilities figures came in at $70000.0 (Q1 2025), $107.6 million (Q4 2024), and $70000.0 (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Jade Biosciences | 973.55 Mn | 973.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 70,000.00 |
| Dec 31, 2024 | 107.60 Mn |
| Sep 30, 2024 | 70,000.00 |
| Jun 30, 2024 | 70,000.00 |
| Mar 31, 2024 | 70,000.00 |
| Dec 31, 2023 | 70,000.00 |
| Sep 30, 2023 | 70,000.00 |
| Jun 30, 2023 | 69,000.00 |
| Mar 31, 2023 | 70,000.00 |
| Dec 31, 2022 | 71,000.00 |
| Sep 30, 2022 | 13,000.00 |
| Jun 30, 2022 | 13,000.00 |
| Mar 31, 2022 | 14,000.00 |
| Dec 31, 2021 | 13,000.00 |